The North America HIV Injection Market would witness market growth of 16.9% CAGR during the forecast period (2023-2030).
The US market dominated the North America HIV Injection Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $905.8 Million by 2029. The Canada market is experiencing a CAGR of 19.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 18.5% during (2023 - 2030).
HIV (Human Immunodeficiency Virus) is a pathogen that targets the immune system's CD4 cells (T cells), which are crucial for defending against infections. HIV reduces the number of CD4 cells in the body, increasing the risk of infection-related cancers and infections if left untreated. A progressive depletion of these cells by HIV may render the body incapable of combating infections and diseases.
HIV is transmitted through contact with specific bodily fluids from an infected individual, including blood, sperm, vaginal fluids, rectal fluids, and breast milk. Sexual contact without protection, sharing needles or syringes with an infected person, and transmission from mother to child during childbirth or breastfeeding are the most prevalent modes of HIV transmission.
A significant public health concern is the increasing prevalence of HIV in North America, especially in certain populations and geographic regions. An increasing prevalence of HIV is also being observed in Canada. The Government of Canada reports that with 1,472 new cases, representing an 11.3% increase, the national rate of new HIV diagnoses for 2021 stood at 3.8 per 100,000 population. Hence, all of these factors will aid in the market's growth.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America HIV Injection Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $905.8 Million by 2029. The Canada market is experiencing a CAGR of 19.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 18.5% during (2023 - 2030).
HIV (Human Immunodeficiency Virus) is a pathogen that targets the immune system's CD4 cells (T cells), which are crucial for defending against infections. HIV reduces the number of CD4 cells in the body, increasing the risk of infection-related cancers and infections if left untreated. A progressive depletion of these cells by HIV may render the body incapable of combating infections and diseases.
HIV is transmitted through contact with specific bodily fluids from an infected individual, including blood, sperm, vaginal fluids, rectal fluids, and breast milk. Sexual contact without protection, sharing needles or syringes with an infected person, and transmission from mother to child during childbirth or breastfeeding are the most prevalent modes of HIV transmission.
A significant public health concern is the increasing prevalence of HIV in North America, especially in certain populations and geographic regions. An increasing prevalence of HIV is also being observed in Canada. The Government of Canada reports that with 1,472 new cases, representing an 11.3% increase, the national rate of new HIV diagnoses for 2021 stood at 3.8 per 100,000 population. Hence, all of these factors will aid in the market's growth.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F.Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Market Report Segmentation
By Distribution Channel- Hospital Pharmacy
- Drugs Stores & Retail Pharmacies
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America HIV Injection Market by Distribution Channel
Chapter 5. North America HIV Injection Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F. Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Methodology
LOADING...
